To solve this point, a well-established transposon-based mouse autochthonous model of liver cancer, in which intrahepatic delivery of oncogenes, such as a combination of c-Myc, Cas9, and a single guide RNA targeting TP53 (c-Myc/sgTP53) or a combination of myr-AKT and β-catenin (AKT/β-catenin), by hydrodynamic tail vein injection (HDI) that leads to the initiation of liver cancers, was first applied in LKO and CTRL mice. The gene discussed is TP53; the disease is liver cancer.